Trial Profile
Phase I Trial of Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 21 Nov 2018
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Lenalidomide (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions
- 17 Feb 2015 Trial phase has been changed from I/II to I; accordingly trial focus changed as reported by ClinicalTrials.gov record.
- 04 Mar 2014 Status changed from active, no longer recruiting to discontinued, as per ClinicalTrials.gov record.
- 11 Feb 2014 Planned End Date changed from 1 Apr 2014 to 1 Apr 2015, as per ClinicalTrials.gov record.